Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis

  • By

  • November 16, 2026

  • 7 min

Share

Objective:

To identify pericyte changes associated with pulmonary fibrosis and investigate FOXF1’s role in regulating those changes.

Approach:
  • Cell identification: Researchers used single-cell RNA sequencing and tissue staining to examine human lung datasets and mouse models, identifying normal Peri1 pericytes and a Peri2 population found only in fibrotic lungs.
  • Functional studies: They tested the effects of removing or increasing FOXF1 in pericytes in mouse fibrosis models and examined how signals from human pericytes affected fibroblasts in laboratory experiments.
Key Findings:
  • Peri2 cells had reduced normal pericyte markers and increased collagen and other scar-related genes; FOXF1 levels were reduced in these cells.
  • Removing FOXF1 from pericytes worsened fibrosis-related outcomes in mouse models.
  • Increasing FOXF1 in mice reduced lung collagen and scarring and improved measures including oxygen levels, including when raised after injury.
  • Human pericytes lacking FOXF1 released signals that increased fibroblast movement, multiplication, and scar-related gene activity.
Interpretation:

The study identifies a fibrotic pericyte population and a FOXF1-related signaling pathway as potential research targets. The cause-and-effect findings are preclinical; human data show an association between lower FOXF1 and more severe disease, not treatment benefit.

Limitations:
  • The FOXF1 intervention findings come from mouse models and laboratory-grown human pericytes; they do not establish that treatment would reverse pulmonary fibrosis in patients.
  • Further work is needed to identify drug targets, test them in additional models and patient lung tissue, develop pericyte-specific delivery, and assess safety.
Conclusion:

The authors describe FOXF1 and related pericyte signaling genes as possible targets for future investigation. Clinical trials would require additional preclinical research.

Original Source(s)

Related Content